Iovance Biotherapeutics vs Krystal Biotech
IOVA and KRYS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IOVA and KRYS compare
Krystal Biotech is the larger company, worth 2.6 times as much as Iovance Biotherapeutics ($9.8B against $3.8B).
Iovance Biotherapeutics grew revenue faster over the last twelve months (34.5% versus 22.6% for Krystal Biotech).
Krystal Biotech keeps more of each dollar of sales as profit, with a net margin of 54.8% compared with −89.1% at Iovance Biotherapeutics.
Krystal Biotech scores higher on the StockData Score (10 against 9 for Iovance Biotherapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IOVA | KRYS |
|---|---|---|
| Size and price | ||
| Market cap | $3.8B | $9.8B |
| Share price | $8.48 | $332.29 |
| Change, 1 year | 324% | 79.6% |
| Change, 5 years | −66.1% | 548% |
| Beta (5Y) | 1.23 | 0.84 |
| Employees | 975 | 295 |
| StockData Score | ||
| Total score | 9 | 10 (better) |
| Valuation score | 0 | 0 |
| Growth score | 2 (better) | 1 |
| Performance score | 1 | 3 (better) |
| Health score | 6 | 6 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 41.6× |
| P/S | 11.8× (better) | 22.3× |
| P/B | 5.2× (better) | 7.2× |
| EV/EBITDA | – | 45.5× |
| P/FCF | – | 38.2× |
| FCF yield | −7.7% | 2.6% (better) |
| Fair value | $4.11 | $157.63 |
| Margin of safety | −107% (better) | −111% |
| Growth | ||
| Revenue growth (TTM) | 34.5% (better) | 22.6% |
| Net income growth (TTM) | – | 64.6% |
| EPS growth (TTM) | – | 62.2% |
| Profitability | ||
| Gross margin | 48.4% | – |
| Operating margin | −92.7% | 44.9% (better) |
| Net margin | −89.1% | 54.8% (better) |
| FCF margin | −91.2% | 58.5% (better) |
| Return on equity | −40.4% | 20.1% (better) |
| Return on invested capital | −57.0% | 45.3% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 4.35 | 8.32 (better) |
| Altman Z-score | 8.14 | 43.30 (better) |
| Piotroski F-score | 4 | 6 (better) |
| Dividends and buybacks | ||
| Buyback yield | −7.6% | – |
| Shareholder yield | −7.6% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 63.3% | 102% |
| Held by insiders | 0.39% | 17.2% |
| Insider net buying, 12 months | – | −$105M |
| Short interest, % of float | 14.4% | 14.2% |
Go deeper
- IOVA stock overview
- IOVA income statement
- IOVA valuation and score
- KRYS stock overview
- KRYS income statement
- KRYS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.